Atossa Therapeutics, Inc. (ATOS)
$
0.64
-0.05 (-7.81%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, specializes in the discovery and development of medicines targeting oncology and infectious diseases. The company's lead program, Endoxifen, which is an active metabolite of tamoxifen, is currently undergoing Phase II clinical trials aimed at treating and preventing breast cancer. Additionally, Atossa is advancing its development of AT-H201, an inhalation therapy designed to enhance lung function in severely ill and hospitalized COVID-19 patients, and AT-301, a proprietary drug candidate for nasal administration in those diagnosed with COVID-19. Moreover, the company is pursuing immunotherapy and chimeric antigen receptor therapy programs targeting breast cancer treatment. A notable collaboration exists with the Dana-Farber Cancer Institute, Inc. to foster research into cytokine-coated nanoparticles for breast cancer therapy. In its financial pursuits, the company earned an interest income of $4,343,000.00 showcasing its financial investments. The income before tax ratio is 0.00 reflecting the pre-tax margin, while the net total of other income and expenses amounts to $1,283,000.00 indicating non-core financial activities. The operating expenses total $31,377,000.00 encompassing various operational costs incurred by the company, and its diluted EPS stands at -$0.24 accounting for potential share dilution. Turning to Atossa’s market positioning, the stock is affordable at $0.68 making it suitable for budget-conscious investors. The stock has an average trading volume of 647,290.00 indicating moderate liquidity, which may appeal to a range of investors. With a market capitalization of $82,991,724.00 the company is classified as a small-cap player, providing unique investment opportunities. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, which is driving innovation and growth within the biopharmaceutical space. This combination of financial performance and strategic focus positions Atossa Therapeutics, Inc. as a noteworthy entity for consideration among potential investors.
Is Atossa Therapeutics, Inc. (ATOS) a good investment?
Investing in Atossa Therapeutics, Inc. (ATOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Atossa Therapeutics, Inc. (ATOS)'s stock forecast?
Analysts predict Atossa Therapeutics, Inc. stock to fluctuate between $0.63 (low) and $2.31 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Atossa Therapeutics, Inc.'s market capitalization?
As of 2025-04-04, Atossa Therapeutics, Inc.'s market cap is $82,991,724, based on 129,169,999 outstanding shares.
How does Atossa Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Atossa Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Atossa Therapeutics, Inc. (ATOS) stock?
To buy Atossa Therapeutics, Inc. (ATOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATOS. Place an order (Market, Limit, etc.).
What is the best time to invest in Atossa Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Atossa Therapeutics, Inc. stock ever split?
Atossa Therapeutics, Inc.'s last stock split was 1:12 on 2018-04-20.
How did Atossa Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.24 | Growth: 14.29%.
Where can I find Atossa Therapeutics, Inc.'s investor relations reports?
Visit https://www.atossatherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Atossa Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Atossa Therapeutics, Inc. stock?
All-time high: $9.80 (2021-06-25) | All-time low: $0.50 (2022-12-28).
What are the key trends affecting Atossa Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
7 days ago
Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com
10 days ago
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call.
globenewswire.com
10 days ago
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments.
globenewswire.com
15 days ago
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time
globenewswire.com
24 days ago
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that pursuing a metastatic indication may offer a more efficient regulatory pathway to deliver (Z)-endoxifen to women in urgent need, and simultaneously plans to work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy, that often require larger and longer clinical trials.
globenewswire.com
2 months ago
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention (CDC). This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City.
globenewswire.com
2 months ago
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board's (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the “'334 patent”).
globenewswire.com
2 months ago
SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company's clinical programs and recent events. The full text of the letter follows:
zacks.com
3 months ago
Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.
globenewswire.com
4 months ago
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: ATOS SE 2024" company profile has been added to ResearchAndMarkets.com's offering.
See all news
